抗小鼠CD8a单抗(克隆号YTS 169.4)学术文献引用与CD8+ T细胞清除应用研究

在肿瘤免疫学、感染免疫以及自身免疫性疾病的研究中，阐明 CD8+ 细胞毒性 T 淋巴细胞（CTL）的功能机制通常需要借助特异性的体内细胞清除工具。抗小鼠 CD8a 单克隆抗体（克隆号 YTS 169.4）作为靶向小鼠 CD8a 亚基的经典抗体克隆，被广泛用于体内（In Vivo）特异性耗竭 CD8+ T 细胞。

由 Syd Labs 研发的体内实验级重组抗小鼠 CD8a 单克隆抗体（Rat IgG2b Kappa，货号：PA007166.r2b），提取自大鼠抗小鼠 CD8a 单抗 YTS 169.4 克隆的可变区序列，并采用哺乳动物细胞表达系统进行重组表达。该抗体具备高纯度、极低内毒素以及优异的批次间一致性，能有效避免传统杂交瘤抗体带来的非特异性干扰。

一、 抗小鼠 CD8a 单克隆抗体（克隆号 YTS 169.4）20 篇代表性学术文献

以下整理了研究团队使用 YTS 169.4 克隆抗小鼠 CD8a 单抗在放射治疗联合免疫阻断、PARP/WEE1 抑制剂增敏、溶瘤病毒疗法及昼夜节律抗肿瘤反应等前沿领域发表的 20 篇 PMC 权威学术文献：

1. CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
2. RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers
3. P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties
4. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
5. Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models
6. Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes
7. Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells
8. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
9. Dendritic cells direct circadian anti-tumour immune responses
10. Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
11. Immunity to Cryptosporidium muris infection in mice is expressed through gut CD4+ intraepithelial lymphocytes
12. Decorin Potentiates Interferon-γ Activity in a Model of Allergic Inflammation
13. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1
14. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
15. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling
16. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
17. Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
18. Murine Model of Interstitial Cytomegalovirus Pneumonia in Syngeneic Bone Marrow Transplantation: Persistence of Protective Pulmonary CD8-T-Cell Infiltrates after Clearance of Acute Infection
19. Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy
20. A cytotoxic T cell inspired oncolytic nanosystem promotes lytic cell death by lipid peroxidation and elicits antitumor immune responses

图：Syd Labs PA007166.r2b 体内实验级重组抗小鼠CD8a单克隆抗体（克隆号YTS 169.4）

二、 Syd Labs 重组抗小鼠 CD8a 单抗（YTS 169.4）产品特性

Syd Labs 体内实验级重组抗小鼠 CD8a 单克隆抗体（货号：PA007166.r2b）在多项研究应用中展现出显著优势：

• 重组表达技术：通过基因工程重组技术在哺乳动物细胞中表达，严格控制分子结构，批次间重现性极佳。
• 体内实验品质：超低内毒素控制，不含防腐剂，适应体内给药严格要求，避免产生非特异性免疫应答。
• 多领域应用支持：除体内 CD8+ T 细胞耗竭（Depletion）外，还适用于蛋白质印迹（Western Blot）、免疫组织化学（IHC）及流式细胞术（FC）等多种分析手段。

三、 产品技术规格与获取途径

如需获取更多关于 Syd Labs 重组抗小鼠 CD8a 单抗（克隆号 YTS 169.4）的产品说明书、应用实验指导，或咨询授权代理事宜，欢迎通过以下方式联系：

• 服务平台：武汉多找找科技有限公司（www.duozhaozhao.com）
• 企业微信：duozhaozhao2024

声明：多找找展示的产品及服务信息如有变更，恕不另行通知。除特殊说明外，相关目录及定制产品仅供科研使用，不得用于临床诊断或治疗。